News
ZLAB
17.78
-3.00%
-0.55
Weekly Report: what happened at ZLAB last week (1222-1226)?
Weekly Report · 10h ago
Zai Lab rises 7.4%
TipRanks · 5d ago
Zai Lab Receives Approval In China For Schizophrenia Drug COBENFY
NASDAQ · 5d ago
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug
Benzinga · 6d ago
Morning Movers: Novo Nordisk gains after Wegovy pill approved
TipRanks · 6d ago
Zai Lab announces China NMPA approval for Cobenfy
TipRanks · 6d ago
Zai Lab Receives China Approval For Its New Drug Application For COBENFY To Treat Schizophrenia In Adults
Benzinga · 6d ago
Zai Lab Wins NMPA Approval for COBENFY Schizophrenia Treatment in China
Reuters · 6d ago
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
Barchart · 6d ago
Weekly Report: what happened at ZLAB last week (1215-1219)?
Weekly Report · 12/22 09:45
Zai Lab Chief Legal Officer Frazor Titus Edmondson III Reports Disposal of Common Shares
Reuters · 12/18 21:35
Weekly Report: what happened at ZLAB last week (1208-1212)?
Weekly Report · 12/15 09:49
Zai Lab Begins First Human Trial of New Eczema Drug Candidate ZL-1503
Benzinga · 12/08 12:15
Zai Lab doses first patient in ZL-1503 trial
TipRanks · 12/08 12:15
ZAI LAB ANNOUNCES DOSING OF FIRST PARTICIPANT IN GLOBAL PHASE 1/1B STUDY OF ZL-1503, AN IL-13/IL-31R BISPECIFIC ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS
Reuters · 12/08 12:00
Weekly Report: what happened at ZLAB last week (1201-1205)?
Weekly Report · 12/08 09:49
ZAI LAB ANNOUNCES UPDATES TO CHINA’S NATIONAL REIMBURSEMENT DRUG LIST
Reuters · 12/07 05:11
Weekly Report: what happened at ZLAB last week (1124-1128)?
Weekly Report · 12/01 09:46
Zai Lab Chief Legal Officer Edmondson Frazor Titus III Reports Sale of Common Shares
Reuters · 11/25 21:12
Weekly Report: what happened at ZLAB last week (1117-1121)?
Weekly Report · 11/24 09:50
More
Webull provides a variety of real-time ZLAB stock news. You can receive the latest news about Zai Lab Limited through multiple platforms. This information may help you make smarter investment decisions.
About ZLAB
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.